Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.51 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | PTPRC | P08575 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087299 | 0.83 | MAOB (0.66) | MAOBFFAR4FFAR1PTPRCPTPN1 | |
| SCHEMBL2088377 | 0.81 | MAOB (1.00) | MAOBMAOASPHK2SPHK1SRD5A2 | |
| SCHEMBL1008781 | 0.80 | NR4A2 (0.72) | MAOBMAOAFFAR4FFAR1PTPRC | |
| SCHEMBL4759812 | 0.80 | MAOB (0.65) | MAOBMAOAFFAR4FFAR1ADAMTS4 | |
| SCHEMBL2086626 | 0.80 | MAOB (0.68) | MAOBFFAR4FFAR1PTPRCPTPN1 | |
| SCHEMBL1007847 | 0.78 | L3MBTL1 (0.65) | FFAR4FFAR1PTPRCPTPN1NR4A2 | |
| SCHEMBL958582 | 0.78 | EGFR (0.69) | MAOBFFAR4FFAR1SRD5A2NR4A2 | |
| SCHEMBL12423202 | 0.74 | MAOB (0.68) | MAOBMAOAFFAR4FFAR1SPHK2 | |
| SCHEMBL365767 | 0.74 | MAOB (0.67) | MAOBMAOASPHK2SPHK1SRD5A2 | |
| SCHEMBL2086520 | 0.74 | FFAR1 (0.50) | MAOBFFAR4FFAR1NR4A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461323-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-10-09 | — | — | EP | claimed |
| JP-4711621-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| CN-100344616-C | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORP (US) | 2007-10-24 | — | — | CN | claimed |
| US-7101910-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2006-09-05 | — | — | US | claimed |
| CN-1608055-A | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORP (US) | 2005-04-20 | — | — | CN | claimed |
| EP-1461323-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2004-09-29 | — | — | EP | claimed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | claimed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | claimed |
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2268141-B1 | COMPOUND AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9115072-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-08-25 | — | — | US | disclosed |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-05-20 | — | — | US | disclosed |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | disclosed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885MAOA 1265/4885FFAR4 71/4885 |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885MAOA 1265/4885FFAR4 71/4885 |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885MAOA 1265/4885FFAR4 71/4885 |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885MAOA 1265/4885FFAR4 71/4885 |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885MAOA 1265/4885FFAR4 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.